Agilon Health (AGL) Stock Looks Discounted Even After A 482% Run
agilon health has delivered a very large year to date gain of 481.9%, yet its latest valuation checks still point to shares looking cheap on several measures. This sets up a clear tension between recent momentum and what the numbers currently suggest about pricing.
- The year to date return of 481.9% leaves existing shareholders with substantial gains, and raises the bar for new buyers who now need stronger fundamentals to justify the move.
- Expectations for agilon health's ability to grow its healthcare platform can support today’s price, while any setbacks in execution or pressure on margins may quickly change how sustainable this valuation looks.
- The stock screens as undervalued in 5 of 6 valuation checks, so the broader picture currently leans cheap rather than expensive.
The issue now is whether agilon health's current share price still reflects a genuine discount, or if the strong run has already absorbed most of that valuation cushion.
Is agilon health a Bargain on Sales?
The P/S ratio is a useful lens for agilon health because the business is still focused on scaling its healthcare platform and sales offer a cleaner anchor than earnings or book value. On this measure, agilon health trades on a P/S of about 0.3x, which is far below the Healthcare industry average of 1.4x and also well under the peer group average of 2.4x.
The tailored fair P/S multiple for agilon health is 0.5x, which already factors in its specific growth profile, risk and margins. With the current P/S sitting meaningfully under that fair ratio, the stock screens as trading at a lower valuation both against the broader sector and against what this model suggests might be reasonable for the company’s characteristics.
Overall, agilon health appears to trade at a lower valuation on the P/S multiple, with the current pricing implying a sizeable discount to both industry norms and its own fair ratio.
See what the numbers say about this price — find out in our valuation breakdown.
The agilon health Narrative: What Would Justify Today's Price?
Simply Wall St Narratives for agilon health pick up where this valuation puzzle leaves off by spelling out which paths for growth, margins and earnings would need to play out for the stock to look meaningfully mispriced in either direction at today’s level. Each Narrative anchors its number to a clear view on how agilon health's opportunities and risks evolve, giving you a reference point to revisit as fresh results and updates come through.
Community views on agilon health sit at opposite ends, with one side seeing a sizable discount and the other flagging a stretched setup.
Bull case: 29% undervalued
"agilon's value-based care platform, enabled by AI and physician partnerships, is well positioned for durable growth and market share gains as the industry shifts…"
Read the full Bull Case to see why agilon health could be undervalued
Bear case: 345% overvalued
"Market exits, cost pressures, and payer negotiation risks threaten to undermine recurring revenue streams and limit sustainable growth in the value-based care sector…"
Read the full Bear Case to see why agilon health could be overvalued
Do you think there's more to the story for agilon health? Head over to our Community to see what others are saying!
The Bottom Line
agilon health still screens as undervalued on sales and other market multiples, even after a very large year to date move. This is why its broader valuation checks look strong rather than stretched. For you, the real question is whether the current discount reflects mispricing or fairly prices the risks around execution, margins and market exits highlighted in the bear case. The crux of the debate from here is simple: whether agilon health can scale its value based care platform without eroding profitability, and, if that happens, whether the current P/S discount closes or proves to be a value trap.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com